stars 1 stars 2 stars 3

Kantify is a Brussels-based Frontier Lab using AI to discover new medicines against previously undruggable targets. The company was built on the conviction that patients with intractable targets deserve access to molecules that conventional methods cannot reach. Kantify's platform, Sapian, is an AI-native, orthogonal approach to drug discovery. It integrates target identification with non-structure-based small molecule design—pioneering a method that requires no experimental structural data and operates independently of traditional screening infrastructures. Sapian screens billions of compounds in silico, combining advanced multi-parameter optimization with proteome-wide selectivity.

Website http://www.kantify.com
Employees 12 (7 on RocketReach)
Founded 2017
Phone +32 484 91 42 17
Technologies
Industry Biotechnology Research, Artificial Intelligence, Big Data, Data and Analytics, Data Analytics, Science and Engineering, Retail Analytics, Software, Pricing, Consulting, FinTech, Financial Services, Machine Learning, Natural Language Processing, Predictive Analytics
Web Rank 16 Million
Keywords Ai Drug Discovery, Ai Healthcare Technology, Computational Drug Design, Precision Medicine Ai, Biotechnology Ai, Drug Discovery Platform, In Silico Drug Discovery, Therapeutic Ai, Innovative Drug Development
Competitors Microsoft, IBM, Google, DataRobot, Dataiku, Alteryx, H2O.ai, Data Science Leaders Podcast, Zaloni, Altair RapidMiner +41 more (view full list)

Kantify Questions

Segolene Martin is the CEO - Cofounder of Kantify.

7 people are employed at Kantify.

Top Kantify Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users